106 related articles for article (PubMed ID: 18254778)
1. Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast.
Fernandez-Aguilar S; Noël JC
APMIS; 2008 Jan; 116(1):33-40. PubMed ID: 18254778
[TBL] [Abstract][Full Text] [Related]
2. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes.
Miyazaki J; Hokari R; Kato S; Tsuzuki Y; Kawaguchi A; Nagao S; Itoh K; Miura S
Oncol Rep; 2002; 9(6):1307-12. PubMed ID: 12375039
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical visualisation of cathepsin-D expression in breast cancer.
Barthell E; Mylonas I; Shabani N; Kunze S; Kuhn C; Jeschke U; Friese K
Anticancer Res; 2007; 27(4A):2035-9. PubMed ID: 17649818
[TBL] [Abstract][Full Text] [Related]
5. Microvessel and lymphatic density in tubular carcinoma of the breast: comparative study with invasive low-grade ductal carcinoma.
Fernandez-Aguilar S; Jondet M; Simonart T; Nöel JC
Breast; 2006 Dec; 15(6):782-5. PubMed ID: 16931017
[TBL] [Abstract][Full Text] [Related]
6. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin-D expression in breast lesion: an immunohistochemical study.
Brujan I; Mărgăritescu C; Simionescu C; Pirici D; Fronie A; Foarfă C; Stepan A; Vrabete M
Rom J Morphol Embryol; 2009; 50(1):31-9. PubMed ID: 19221643
[TBL] [Abstract][Full Text] [Related]
8. CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.
Looi LM; Cheah PL; Zhao W; Ng MH; Yip CH
Malays J Pathol; 2006 Dec; 28(2):83-6. PubMed ID: 18376796
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein D expression in metastasic lymph nodes of breast cancer.
Lamelas ML; Vázquez J; Enguita MI; Rodríguez JC; González LO; Merino AM; Vizoso F
Int J Surg Investig; 2000; 2(4):285-93. PubMed ID: 12678530
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin D in invasive ductal NOS, medullary, lobular and mucinous breast carcinoma. An immunohistochemical study.
Bedner E; Harezga B; Osborn M; Domagała W
Pol J Pathol; 1995; 46(1):11-5. PubMed ID: 7780691
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical expression of cathepsin D in colorectal cancer.
Valentini AM; Pirrelli M; Armentano R; Caruso ML
Anticancer Res; 1996; 16(1):77-80. PubMed ID: 8615673
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 upregulation during tumor progression in head and neck cancer.
Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ
Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
[TBL] [Abstract][Full Text] [Related]
14. Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis.
Cheng AL; Huang WG; Chen ZC; Zhang PF; Li MY; Li F; Li JL; Li C; Yi H; Peng F; Duan CJ; Xiao ZQ
J Proteome Res; 2008 Jun; 7(6):2415-26. PubMed ID: 18433155
[TBL] [Abstract][Full Text] [Related]
15. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of cathepsin D in low grade breast invasive cancer.
Lazaris AC; Theodoropoulos GE; Diamantopoulos AK; Anastassopoulos PD; Davaris PS
Anticancer Res; 1997; 17(4A):2651-5. PubMed ID: 9252696
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands.
Ferrazzo KL; Alves SM; Santos E; Martins MT; de Sousa SM
Oral Oncol; 2007 Jul; 43(6):580-5. PubMed ID: 16996782
[TBL] [Abstract][Full Text] [Related]
18. Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma.
Dvalishvili I; Charkviani L; Charkviani T; Turashvili G; Burkadze G
Georgian Med News; 2005 Sep; (126):27-31. PubMed ID: 16234588
[TBL] [Abstract][Full Text] [Related]
19. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
